Health
Moderna’s stock has surged 488% in 2020: Is it a buy for 2021? – Motley Fool Australia
This smaller biotech company attracted a lot of attention in 2020, but is it still worth an investment?
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
All eyes were on the biotech Moderna(NASDAQ: MRNA) in 2020. It wasn’t quite a popular name in the pharmaceutical space, as it has no approved products on the market yet. But its sudden entry in the COVID-19 vaccine competition grabbed a lot of attention, and it became the second company to win approval in a race with dozens of players. No wonder its stock has surged 488% so far this year,…
-
General10 hours agoFerries and celebrities as pollies dash to win the west
-
Noosa News15 hours agoCSIRO, winemakers pair to breed mildew, climate-resistant grapevines
-
Noosa News12 hours agoChild killer Rick Thorburn who murdered Tiahleigh Palmer found dead in jail cell
-
Noosa News19 hours agoSpinach salads back on supermarket shelves amid E. coli probe